Callan JMB Supports Immune Platform Scale-Up

Callan JMB is providing oversight for the U.S. scale-up of a multi-indication immune platform, advancing it to Phase 2b/3 trials. This support ensures manufacturing and supply chain integrity, alongside federal readiness for the platform's broad application. The independent oversight reinforces confidence in the platform's development and potential for widespread use across various medical indications. This milestone signifies progress in bringing innovative immunotherapies to market, addressing diverse health needs with a scalable and robust manufacturing process.